MDS Treatment Information
MDS, or myelodysplastic syndrome, is a collection of conditions that can occur when the blood-forming cells in the bone marrow become damaged. Some of these conditions are mild and simple to manage, while other, more aggressive forms can develop into acute myeloid leukemia (AML), a cancer in which immature blood cells grow uncontrollably. Regardless of the type of MDS a patient has been diagnosed with, expert management of the condition is essential.
Moffitt Cancer Center’s Malignant Hematology Program, which has one of the largest MDS programs in the nation, provides comprehensive, multispecialty treatment for patients with all forms of MDS and AML. We understand that each patient responds differently to therapy, so our experienced team of oncologists, hematologists, medical oncologists, supportive care providers and other team members thoroughly assess each patient’s case to determine the most appropriate options for working toward remission and bringing blood cell counts as close to normal as possible. A patient’s individualized recommendation might include a combination of the following MDS therapies:
- Targeted therapy
- Stem cell and bone marrow transplants
- Clinical trials
At Moffitt, all MDS therapies are provided in a single location, making it easier for patients to access the outstanding treatments they deserve without the stress of traveling from clinic to clinic. Furthermore, we also offer a complete range of supportive care services, such as side effect management and psychosocial counseling, giving patients a convenient way to improve their quality of life during treatment.
Not only is Moffitt a recognized leader in MDS treatment, but we are also committed to learning more about these conditions and how they can eventually be cured. With a dedicated research team working hand in hand with our expert oncologists, Moffitt is paving the way for better MDS treatment options and patient outcomes. For these efforts, we have been named a Comprehensive Cancer Center by the National Cancer Institute – the only such center based in Florida. Our Malignant Hematology Program leads the way in clinical trials and has led to the approvals of several innovative drugs for MDS treatment.